Available IPD datapackage for study 'Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke'
Abstract
The primary objective of the study is to assess the clinical effects of natalizumab versus placebo in acute ischemic stroke on clinical measures of functional independence and activities of daily living. The secondary objective of the study is to explore dose and exposure response and the clinical treatment effects of natalizumab versus placebo in acute ischemic stroke on the following: measures of independence, activities of daily living, neurologic function, quality of life, cognition, and safety and tolerability
Fields of Study & Subjects
Acute Ischemic Stroke Management
Stroke Rehabilitation and Recovery
Neurological Disorders and Treatments
Publication details
- Journal / source
- Vivli
- Publication date
- 18 January 2026
- Language
- EN
- Document type
- Dataset